<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01193582</url>
  </required_header>
  <id_info>
    <org_study_id>B1841008</org_study_id>
    <secondary_id>B1841008</secondary_id>
    <nct_id>NCT01193582</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria</brief_title>
  <acronym>6114A1-4000-CN</acronym>
  <official_title>A Phase 4, Open-label Trial to Assess the Safety, Tolerability and Immunogenicity of Prevenar in Older Infants and Young Children in China Who Are Naive to Previous Pneumococcal Vaccination.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A vaccine called Prevenar is already approved for use in China for vaccination of children
      younger than 6 years old against infections caused by Streptococcus pneumoniae.

      This study is to measure the amount of antibodies (antibodies help people fight off diseases)
      Chinese children aged between 121 days and 6 years (72 months) produce when given Prevenar.
      The study will also provide more data on how safe and well tolerated Prevenar is in Chinese
      children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar</measure>
    <time_frame>1 month after last dose in each group</time_frame>
    <description>Serotype-specific Pneumococcal Immunoglobulin G (IgG) antibody geometric mean concentration (GMC) after 1 month of last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at Baseline in Each Group</measure>
    <time_frame>Baseline</time_frame>
    <description>Serotype-specific Pneumococcal IgG antibody GMC at baseline for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Third Dose in Group 1</measure>
    <time_frame>1 month after third dose of Prevenar in Group 1</time_frame>
    <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the third dose in Group 1 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 1.</measure>
    <time_frame>Pre-vaccination to 1 month after third dose of Prevenar in Group 1</time_frame>
    <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Second Dose in Group 2</measure>
    <time_frame>1 month after second dose of Prevenar in Group 2</time_frame>
    <description>Serotype-specific Pneumococcal IgG antibody GMC 1 month after the second dose in Group 2 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 2.</measure>
    <time_frame>Pre-vaccination to 1 month after second dose of Prevenar in Group 2</time_frame>
    <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the First Dose in Group 3</measure>
    <time_frame>1 month after first dose of Prevenar in Group 3</time_frame>
    <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the first dose in Group 3 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 3.</measure>
    <time_frame>Pre-vaccination to 1 month after first dose of Prevenar in Group 3</time_frame>
    <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Concentrations Against the 7 Pneumococcal Serotypes Contained in Prevenar at 12 Months After the Last Dose.</measure>
    <time_frame>12 months after the last dose</time_frame>
    <description>Serotype-specific Pneumococcal IgG antibody GMC 12 months after the last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values at 12 Months After the Last Dose.</measure>
    <time_frame>Pre-vaccination to 12 months after the last dose</time_frame>
    <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to 12- month follow-up were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">505</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
4 doses starting from 121 to &lt; 212 days of age</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
3 doses starting from 212 days to &lt; 12 months of age</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
2 doses starting from 12 months to &lt; 24 months of age</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevenar</intervention_name>
    <description>Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
1 dose starting from 24 months to &lt; 72 months of age</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Chinese male or female subjects.

          -  Between 121 days to less than 72 months of age at the time of entry into the study.

        Exclusion Criteria:

          -  Receipt of previous vaccine against Pneumo

          -  Previous anaphylactic reaction to any vaccine or part of a vaccine

          -  Previous proven invasive Pneumo infection

          -  Receipt of investigational drug or device within the proceeding 28 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>121 Days</minimum_age>
    <maximum_age>72 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baolixiang Clinic</name>
      <address>
        <city>Baoli Town,Yongfu County</city>
        <state>Guangxi</state>
        <zip>541902</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangfuxiang Clinic</name>
      <address>
        <city>Guangfu Town, Yongfu County</city>
        <state>Guangxi</state>
        <zip>541803</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luojin Clinic</name>
      <address>
        <city>Luojin Town, Yongfu County</city>
        <state>Guangxi</state>
        <zip>541801</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongfu County CDC</name>
      <address>
        <city>Yongfu County</city>
        <state>Guangxi</state>
        <zip>541800</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongfu County Clinic</name>
      <address>
        <city>Yongfu County</city>
        <state>Guangxi</state>
        <zip>541800</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B1841008&amp;StudyName=A%20Study%20To%20Assess%20The%20Safety%20And%20Effectiveness%20Of%20Prevenar%20In%20Chinese%20Children%20Who%20Have%20Not%20Previously%20Received%20A%20Vaccine%20Against%20Pn</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>August 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2010</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevenar</keyword>
  <keyword>catch-up</keyword>
  <keyword>pneumococcal</keyword>
  <keyword>pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This report presents results following completion of all vaccinations, including data from the 12-month follow-up. This study was conducted at one site in China.</recruitment_details>
      <pre_assignment_details>Participants were enrolled into 1 of 4 groups based on inclusion/exclusion criteria without a screening period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
        </group>
        <group group_id="P4">
          <title>Group 4</title>
          <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Vaccination Series</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="125"/>
                <participants group_id="P4" count="180"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="118"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="89"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 4</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12 Month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="89"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="117"/>
                <participants group_id="P4" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="113"/>
                <participants group_id="P4" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
        </group>
        <group group_id="B4">
          <title>Group 4</title>
          <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="88"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="115"/>
            <count group_id="B4" value="177"/>
            <count group_id="B5" value="467"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at first Vaccination</description>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.3" spread="0.9"/>
                    <measurement group_id="B2" value="9.8" spread="1.4"/>
                    <measurement group_id="B3" value="17.5" spread="4.2"/>
                    <measurement group_id="B4" value="44.5" spread="13.0"/>
                    <measurement group_id="B5" value="24.0" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="244"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar</title>
        <description>Serotype-specific Pneumococcal Immunoglobulin G (IgG) antibody geometric mean concentration (GMC) after 1 month of last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after last dose in each group</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar</title>
          <description>Serotype-specific Pneumococcal Immunoglobulin G (IgG) antibody geometric mean concentration (GMC) after 1 month of last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.90" lower_limit="5.61" upper_limit="8.48"/>
                    <measurement group_id="O2" value="7.16" lower_limit="6.09" upper_limit="8.42"/>
                    <measurement group_id="O3" value="7.53" lower_limit="6.70" upper_limit="8.46"/>
                    <measurement group_id="O4" value="9.45" lower_limit="8.38" upper_limit="10.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 88, 87, 114, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.01" lower_limit="6.24" upper_limit="10.30"/>
                    <measurement group_id="O2" value="5.79" lower_limit="4.64" upper_limit="7.23"/>
                    <measurement group_id="O3" value="4.81" lower_limit="3.89" upper_limit="5.96"/>
                    <measurement group_id="O4" value="6.36" lower_limit="5.32" upper_limit="7.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" lower_limit="3.40" upper_limit="4.96"/>
                    <measurement group_id="O2" value="4.64" lower_limit="3.93" upper_limit="5.47"/>
                    <measurement group_id="O3" value="4.67" lower_limit="4.18" upper_limit="5.21"/>
                    <measurement group_id="O4" value="6.14" lower_limit="5.42" upper_limit="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.75" lower_limit="10.32" upper_limit="15.76"/>
                    <measurement group_id="O2" value="13.02" lower_limit="10.89" upper_limit="15.57"/>
                    <measurement group_id="O3" value="11.98" lower_limit="10.51" upper_limit="13.65"/>
                    <measurement group_id="O4" value="9.86" lower_limit="8.03" upper_limit="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.65" lower_limit="3.81" upper_limit="5.69"/>
                    <measurement group_id="O2" value="4.65" lower_limit="3.86" upper_limit="5.61"/>
                    <measurement group_id="O3" value="5.40" lower_limit="4.78" upper_limit="6.10"/>
                    <measurement group_id="O4" value="7.39" lower_limit="6.41" upper_limit="8.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 87, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.05" lower_limit="3.07" upper_limit="5.36"/>
                    <measurement group_id="O2" value="4.02" lower_limit="3.05" upper_limit="5.31"/>
                    <measurement group_id="O3" value="4.03" lower_limit="3.26" upper_limit="4.98"/>
                    <measurement group_id="O4" value="4.53" lower_limit="3.73" upper_limit="5.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" lower_limit="3.77" upper_limit="5.99"/>
                    <measurement group_id="O2" value="3.95" lower_limit="3.19" upper_limit="4.89"/>
                    <measurement group_id="O3" value="4.18" lower_limit="3.51" upper_limit="4.96"/>
                    <measurement group_id="O4" value="5.64" lower_limit="4.84" upper_limit="6.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at Baseline in Each Group</title>
        <description>Serotype-specific Pneumococcal IgG antibody GMC at baseline for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>Baseline</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at Baseline in Each Group</title>
          <description>Serotype-specific Pneumococcal IgG antibody GMC at baseline for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="125"/>
                <count group_id="O4" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 88, 87, 115, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O2" value="0.01" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O3" value="0.02" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O4" value="0.06" lower_limit="0.05" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 86, 64, 100, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="0.10" upper_limit="0.15"/>
                    <measurement group_id="O2" value="0.16" lower_limit="0.12" upper_limit="0.22"/>
                    <measurement group_id="O3" value="0.27" lower_limit="0.21" upper_limit="0.35"/>
                    <measurement group_id="O4" value="1.30" lower_limit="1.08" upper_limit="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 88, 84, 113, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0.08" upper_limit="0.12"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.08" upper_limit="0.13"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.13" upper_limit="0.21"/>
                    <measurement group_id="O4" value="0.66" lower_limit="0.56" upper_limit="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 88, 87, 115, 177)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.12" upper_limit="0.22"/>
                    <measurement group_id="O2" value="0.04" lower_limit="0.03" upper_limit="0.05"/>
                    <measurement group_id="O3" value="0.03" lower_limit="0.02" upper_limit="0.04"/>
                    <measurement group_id="O4" value="0.36" lower_limit="0.26" upper_limit="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 88, 87, 114, 172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.03" upper_limit="0.06"/>
                    <measurement group_id="O2" value="0.02" lower_limit="0.01" upper_limit="0.02"/>
                    <measurement group_id="O3" value="0.02" lower_limit="0.02" upper_limit="0.03"/>
                    <measurement group_id="O4" value="0.12" lower_limit="0.10" upper_limit="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 88, 85, 115, 169)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="0.09" upper_limit="0.14"/>
                    <measurement group_id="O2" value="0.09" lower_limit="0.07" upper_limit="0.12"/>
                    <measurement group_id="O3" value="0.13" lower_limit="0.10" upper_limit="0.17"/>
                    <measurement group_id="O4" value="0.71" lower_limit="0.57" upper_limit="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 85, 75, 102, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.06" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.06" upper_limit="0.11"/>
                    <measurement group_id="O3" value="0.17" lower_limit="0.12" upper_limit="0.23"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.74" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Third Dose in Group 1</title>
        <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the third dose in Group 1 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after third dose of Prevenar in Group 1</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Third Dose in Group 1</title>
          <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the third dose in Group 1 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.38" lower_limit="5.56" upper_limit="7.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" lower_limit="2.33" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" lower_limit="3.51" upper_limit="4.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.16" lower_limit="9.12" upper_limit="13.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.60" lower_limit="3.80" upper_limit="5.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="2.75" upper_limit="4.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="1.97" upper_limit="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 1.</title>
        <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
        <time_frame>Pre-vaccination to 1 month after third dose of Prevenar in Group 1</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 1.</title>
          <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="453.17" lower_limit="344.56" upper_limit="596.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.10" lower_limit="18.15" upper_limit="29.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.38" lower_limit="33.42" upper_limit="56.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.90" lower_limit="45.95" upper_limit="106.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106.74" lower_limit="76.83" upper_limit="148.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 88)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.52" lower_limit="23.39" upper_limit="45.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.01" lower_limit="24.98" upper_limit="46.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Second Dose in Group 2</title>
        <description>Serotype-specific Pneumococcal IgG antibody GMC 1 month after the second dose in Group 2 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after second dose of Prevenar in Group 2</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the Second Dose in Group 2</title>
          <description>Serotype-specific Pneumococcal IgG antibody GMC 1 month after the second dose in Group 2 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.46" lower_limit="7.36" upper_limit="9.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.67" lower_limit="2.06" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.71" lower_limit="3.91" upper_limit="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.05" lower_limit="6.71" upper_limit="9.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" lower_limit="4.00" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" lower_limit="2.27" upper_limit="4.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.66" lower_limit="2.10" upper_limit="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 2.</title>
        <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
        <time_frame>Pre-vaccination to 1 month after second dose of Prevenar in Group 2</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 2.</title>
          <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="705.95" lower_limit="540.50" upper_limit="922.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.64" lower_limit="11.17" upper_limit="24.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.72" lower_limit="34.22" upper_limit="58.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217.21" lower_limit="152.52" upper_limit="309.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 87)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.90" lower_limit="219.65" upper_limit="460.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 85)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.66" lower_limit="24.28" upper_limit="46.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.77" lower_limit="21.30" upper_limit="44.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the First Dose in Group 3</title>
        <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the first dose in Group 3 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>1 month after first dose of Prevenar in Group 3</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations to the 7 Pneumococcal Serotypes Contained in Prevenar at 1 Month After the First Dose in Group 3</title>
          <description>Serotype-specific Pneumococcal IgG antibody GMC one month after the first dose in Group 3 for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.44" lower_limit="7.25" upper_limit="9.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" lower_limit="1.51" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.77" lower_limit="4.09" upper_limit="5.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.37" lower_limit="2.74" upper_limit="4.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" lower_limit="4.82" upper_limit="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.96" lower_limit="1.55" upper_limit="2.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" lower_limit="2.26" upper_limit="3.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 3.</title>
        <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
        <time_frame>Pre-vaccination to 1 month after first dose of Prevenar in Group 3</time_frame>
        <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values in Group 3.</title>
          <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population consisted of eligible participants in the age range who had received all the assigned vaccination(s), had blood drawn within required time frames, had at least 1 valid and determinate assay result for the proposed analysis, had received no prohibited vaccines, and had no other major protocol violations.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476.49" lower_limit="363.31" upper_limit="624.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" lower_limit="5.50" upper_limit="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.11" lower_limit="22.18" upper_limit="35.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108.18" lower_limit="78.76" upper_limit="148.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="236.39" lower_limit="182.65" upper_limit="305.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.13" lower_limit="11.02" upper_limit="20.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.64" lower_limit="13.43" upper_limit="23.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody Concentrations Against the 7 Pneumococcal Serotypes Contained in Prevenar at 12 Months After the Last Dose.</title>
        <description>Serotype-specific Pneumococcal IgG antibody GMC 12 months after the last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
        <time_frame>12 months after the last dose</time_frame>
        <population>Evaluable immunogenicity population consisted subjects who had received all , assigned vaccination(s), had blood drawn within required time frame for 12 month follow-up blood draw visit, had at least 1 valid and determinate assay result, had received no prohibited vaccines, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Concentrations Against the 7 Pneumococcal Serotypes Contained in Prevenar at 12 Months After the Last Dose.</title>
          <description>Serotype-specific Pneumococcal IgG antibody GMC 12 months after the last dose for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC and corresponding 2-sided 95% CI were evaluated. GMs were calculated using all participants with available data for the specified blood draw.</description>
          <population>Evaluable immunogenicity population consisted subjects who had received all , assigned vaccination(s), had blood drawn within required time frame for 12 month follow-up blood draw visit, had at least 1 valid and determinate assay result, had received no prohibited vaccines, and had no major protocol violations.</population>
          <units>μg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 81, 79, 111, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="0.62" upper_limit="0.98"/>
                    <measurement group_id="O2" value="0.65" lower_limit="0.52" upper_limit="0.82"/>
                    <measurement group_id="O3" value="0.96" lower_limit="0.80" upper_limit="1.14"/>
                    <measurement group_id="O4" value="1.27" lower_limit="1.11" upper_limit="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 81, 78, 109, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" lower_limit="2.41" upper_limit="4.29"/>
                    <measurement group_id="O2" value="2.31" lower_limit="1.77" upper_limit="3.03"/>
                    <measurement group_id="O3" value="2.38" lower_limit="1.89" upper_limit="3.00"/>
                    <measurement group_id="O4" value="4.20" lower_limit="3.49" upper_limit="5.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 81, 79, 111, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit="1.00" upper_limit="1.59"/>
                    <measurement group_id="O2" value="0.98" lower_limit="0.79" upper_limit="1.21"/>
                    <measurement group_id="O3" value="1.44" lower_limit="1.20" upper_limit="1.71"/>
                    <measurement group_id="O4" value="2.23" lower_limit="1.94" upper_limit="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 81, 79, 111, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.84" lower_limit="1.40" upper_limit="2.41"/>
                    <measurement group_id="O2" value="2.18" lower_limit="1.62" upper_limit="2.94"/>
                    <measurement group_id="O3" value="2.61" lower_limit="2.09" upper_limit="3.27"/>
                    <measurement group_id="O4" value="5.19" lower_limit="4.25" upper_limit="6.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 81, 79, 111, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.87" lower_limit="0.69" upper_limit="1.10"/>
                    <measurement group_id="O2" value="0.71" lower_limit="0.59" upper_limit="0.85"/>
                    <measurement group_id="O3" value="0.98" lower_limit="0.84" upper_limit="1.15"/>
                    <measurement group_id="O4" value="1.46" lower_limit="1.24" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 80, 76, 109, 156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" lower_limit="0.95" upper_limit="1.64"/>
                    <measurement group_id="O2" value="1.29" lower_limit="0.85" upper_limit="1.95"/>
                    <measurement group_id="O3" value="1.39" lower_limit="1.03" upper_limit="1.88"/>
                    <measurement group_id="O4" value="2.85" lower_limit="2.28" upper_limit="3.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 81, 78, 110, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="1.07" upper_limit="1.77"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.91" upper_limit="1.59"/>
                    <measurement group_id="O3" value="1.79" lower_limit="1.45" upper_limit="2.21"/>
                    <measurement group_id="O4" value="2.49" lower_limit="2.13" upper_limit="2.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values at 12 Months After the Last Dose.</title>
        <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to 12- month follow-up were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
        <time_frame>Pre-vaccination to 12 months after the last dose</time_frame>
        <population>Evaluable immunogenicity population consisted subjects who had received all , assigned vaccination(s), had blood drawn within required time frame for 12 month follow-up blood draw visit, had at least 1 valid and determinate assay result, had received no prohibited vaccines, and had no major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
          </group>
          <group group_id="O4">
            <title>Group 4</title>
            <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-Pneumococcal Antibody Levels to the 7 Pneumococcal Serotypes Contained in Prevenar Above Vaccination Baseline Values at 12 Months After the Last Dose.</title>
          <description>GMFRs for the 7 pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) from pre-vaccination to 12- month follow-up were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t-distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population consisted subjects who had received all , assigned vaccination(s), had blood drawn within required time frame for 12 month follow-up blood draw visit, had at least 1 valid and determinate assay result, had received no prohibited vaccines, and had no major protocol violations.</population>
          <units>Fold rise</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="117"/>
                <count group_id="O4" value="177"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 (n= 81, 79, 111, 157)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.86" lower_limit="37.61" upper_limit="74.31"/>
                    <measurement group_id="O2" value="50.54" lower_limit="37.47" upper_limit="68.18"/>
                    <measurement group_id="O3" value="52.19" lower_limit="39.75" upper_limit="68.53"/>
                    <measurement group_id="O4" value="21.01" lower_limit="17.04" upper_limit="25.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B (n= 79, 58, 95, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.52" lower_limit="18.57" upper_limit="35.07"/>
                    <measurement group_id="O2" value="15.58" lower_limit="10.18" upper_limit="23.83"/>
                    <measurement group_id="O3" value="7.99" lower_limit="5.98" upper_limit="10.67"/>
                    <measurement group_id="O4" value="3.16" lower_limit="2.70" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V (n= 81, 76, 109, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.73" lower_limit="9.41" upper_limit="17.24"/>
                    <measurement group_id="O2" value="8.97" lower_limit="6.84" upper_limit="11.77"/>
                    <measurement group_id="O3" value="8.40" lower_limit="6.55" upper_limit="10.77"/>
                    <measurement group_id="O4" value="3.35" lower_limit="2.93" upper_limit="3.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 (n= 81, 79, 111, 162)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.19" lower_limit="6.84" upper_limit="15.19"/>
                    <measurement group_id="O2" value="55.55" lower_limit="37.23" upper_limit="82.87"/>
                    <measurement group_id="O3" value="88.27" lower_limit="63.53" upper_limit="122.63"/>
                    <measurement group_id="O4" value="15.67" lower_limit="11.43" upper_limit="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C (n= 81, 79, 110, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.75" lower_limit="14.00" upper_limit="27.87"/>
                    <measurement group_id="O2" value="45.07" lower_limit="33.12" upper_limit="61.33"/>
                    <measurement group_id="O3" value="41.14" lower_limit="32.18" upper_limit="52.59"/>
                    <measurement group_id="O4" value="11.43" lower_limit="9.38" upper_limit="13.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F (n= 80, 74, 109, 150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.06" lower_limit="6.85" upper_limit="14.77"/>
                    <measurement group_id="O2" value="12.62" lower_limit="8.67" upper_limit="18.39"/>
                    <measurement group_id="O3" value="11.15" lower_limit="7.87" upper_limit="15.80"/>
                    <measurement group_id="O4" value="4.19" lower_limit="3.19" upper_limit="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F (n= 79, 67, 97, 159)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.80" lower_limit="13.26" upper_limit="26.66"/>
                    <measurement group_id="O2" value="13.50" lower_limit="9.56" upper_limit="19.04"/>
                    <measurement group_id="O3" value="11.39" lower_limit="8.31" upper_limit="15.61"/>
                    <measurement group_id="O4" value="2.86" lower_limit="2.39" upper_limit="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline through 12 months following last dose of Prevenar</time_frame>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>Participants 121 to &lt;212 days of age and received 4 doses of Prevenar.</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Participants 212 days to &lt;12 months of age (before the first birthday) and received 3 doses of Prevenar.</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Participants 12 to &lt;24 months of age (before the second birthday) and received 2 doses of Prevenar</description>
        </group>
        <group group_id="E4">
          <title>Group 4</title>
          <description>Participants 24 to &lt;72 months of age (before the sixth birthday) and received 1 dose of Prevenar</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

